NASDAQ:ISPC
iSpecimen Inc.
iSpecimen Inc.'s revenue fell 79.2% in fiscal 2025 to $1.9M while operating margin fell to −465.4%, its lowest in 6 years. Free cash flow was −$4.2M, −219.9% of revenue, and the diluted share count rose 547.5%.Summary generated from iSpecimen Inc.'s SEC filings. Latest annual report filed Apr 1, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.9M
Revenue growth−79.2%
Revenue, 5-yr CAGR−25.1%
Gross margin11.2%
Operating margin−465.4%
Net margin−543.7%
ROICn/a
Return on equity−327.8%
Debt / equityn/a
Free cash flow−$4.2M
FCF margin−219.9%
Share count change+547.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11 | 10 | 10 | 9 | 2 |
| Operating income | −6 | −10 | −11 | −13 | −9 |
| Net income | −9 | −10 | −11 | −12 | −10 |
| Free cash flow | −11 | −6 | −6 | −8 | −4 |
Recent filings
- 8-KResults of a shareholder vote
Oct 9, 2026 - DEF 14AProxy statement
Sep 14, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 10, 2026 - 8-KEntry into a material agreement
Sep 4, 2026 - 8-KDirector or officer change
Aug 31, 2026 - 8-KEntry into a material agreement
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KEntry into a material agreement
Aug 11, 2026